Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease | Zendy

Dick de Zeeuw | Zendy; Tadao Akizawa | Zendy; Paul Audhya | Zendy; George L. Bakris | Zendy; Melanie Chin | Zendy; Heidi ChristSchmidt | Zendy; Angie Goldsberry | Zendy; Mark T. Houser | Zendy; Melissa Krauth | Zendy; Hiddo J.L. Heerspink | Zendy; John J.V. McMurray | Zendy; Colin J. Meyer | Zendy; HansHenrik Parving | Zendy; Giuseppe Remuzzi | Zendy; Robert D. Toto | Zendy; Nosratola D. Vaziri | Zendy; Christoph Wanner | Zendy; Janet Wittes | Zendy; Danielle Wrolstad | Zendy; Glenn M. Chertow | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

Author(s) -

Dick de Zeeuw,

Tadao Akizawa,

Paul Audhya,

George L. Bakris,

Melanie Chin,

Heidi ChristSchmidt,

Angie Goldsberry,

Mark T. Houser,

Melissa Krauth,

Hiddo J.L. Heerspink,

John J.V. McMurray,

Colin J. Meyer,

HansHenrik Parving,

Giuseppe Remuzzi,

Robert D. Toto,

Nosratola D. Vaziri,

Christoph Wanner,

Janet Wittes,

Danielle Wrolstad,

Glenn M. Chertow

Publication year - 2013

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1306033

Subject(s) - medicine , kidney disease , type 2 diabetes , diabetes mellitus , renin–angiotensin system , risk factor , endocrinology , disease , stage (stratigraphy) , urology , pharmacology , paleontology , blood pressure , biology

Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research